GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions. Rapt only licensed the therapy, called ozureprubart, from China’s Jemincare Pharmaceutical a year ago. While Jemincare had been evaluating the drug in phase 2 trials for asthma and chronic spontaneous urticaria in China, Rapt took ozureprubart into a phase 2b study in the U.S., Canada and Australia as a prophylactic for patients with food allergies in Oct. 2025.
Read the full article: GSK Pays $2.2B to Buy Rapt for Its Phase 2-Stage Food Allergy Challenger to Xolair //
Source: https://www.fiercebiotech.com/biotech/gsk-pays-22b-buy-rapt-its-phase-2-stage-food-allergy-challenger-xolair